SKCCC is a prolific research institution. Many of the over 100 research laboratories are part of specialized research programs, including the Brain Cancer, Breast & Ovarian Cancer, Cancer Biology, Cancer Chemical & Structural Biology, Cancer Immunology, Cancer Molecular & Functional Imaging, Cancer Prevention & Control, Hematologic Malignancies & Bone Marrow Transplant, Prostate Cancer, and SPORE programs. The Bloomberg–Kimmel Institute for Cancer Immunotherapy was founded with in 2016 two $50 million gifts from Michael R. Bloomberg and Sidney Kimmel, both of whom have made extensive donations to the university in the past, and an additional $25 million by additional supporters. Drew Pardoll is the founding director.
Lasker Award 2006 and Nobel Prize 2009 – Carol Greider, Professor and Director of Molecular Biology and Genetics in the Johns Hopkins Institute for Basic Biomedical Science
Lasker Award 2016 and Nobel Prize 2019 – Gregg L. Semenza, Professor of Genetic Medicine, Pediatrics, Medicine, Oncology, Radiation Oncology, and Biological Chemistry
SKCCC is spread across several facilities. Research is mainly done in two buildings. The Bunting Blaustein Cancer Research Building opened in 1999 and is a ten-story laboratory building housing the programs for research in cancer biology, hematological malignancies, urological oncology, gastrointestinal cancer, solid tumor research, pharmacology, and experimental therapeutics, and cancer prevention and control. The Koch Cancer Research Building opened in 2006 and is connected to the Bunting Blaustein Building and houses the prostate, brain, pancreas, skin, lung, and head and neck cancer research programs. Patient care is given in the Harry and Jeanette Weinberg Building, a 350,000 sq ft, 9-floor building connected to the main hospital by an enclosed walkway. It has 62 medical beds, 72 surgical beds, and 20 ICU beds. The Cancer Counseling Center is located in the Hackerman-Patz Patient and Family Pavilion and offers information about early detection and prevention, palliative care, and programs for survivors. The Skip Viragh Outpatient Cancer Building is expected to open in Spring 2018. Named after Albert P. “Skip” Viragh Jr, a mutual fund investor who died of pancreatic cancer in 2003, this new building will provide services to over 180 patients with solid tumor daily and enable the Harry and Jeanette Weinberg Building to expand its services to leukemia and myeloma. It is designated as a Magnet hospital. SKCCC was featured in the 2015 Ken Burns documentary.
